Recruiting OBSERVATIONAL NCT04807114

A Single-cell Approach to Identify Biomarkers of Efficacy and Toxicity for ICI in NSCLC

A Single-cell Approach to Identify Biomarkers of Efficacy and Toxicity for Immune Checkpoint Blockade in Non-small Cell Lung Cancer

Sponsor: KU Leuven

Conditions Immunotherapy Lung Diseases, Interstitial NSCLC

Interventions Chemotherapy + Immune checkpoint inhibitor Immune checkpoint inhibitor

Updated 7 times since 2021 Last updated: Jun 28, 2024 Started: Feb 1, 2020 Primary completion: Jan 31, 2025 Completion: Jan 31, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Immunotherapy and Lung Diseases, Interstitial, this trial is actively recruiting participants. The trial is conducted by KU Leuven and has accumulated 7 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Recruiting
Aug 2024 — Sep 2024 [monthly]

Recruiting
Jul 2024 — Aug 2024 [monthly]

Recruiting
Apr 2023 — Jul 2024 [monthly]

Recruiting
Nov 2022 — Apr 2023 [monthly]

Recruiting

▶ Show 2 earlier versions

Dec 2021 — Nov 2022 [monthly]

Recruiting
Apr 2021 — Dec 2021 [monthly]

Recruiting

First recorded

Feb 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

KU Leuven
Universitaire Ziekenhuizen KU Leuven

Data source: Universitaire Ziekenhuizen KU Leuven

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Leuven, Belgium